Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise

Health, Fitness & Food

An Eli Lilly & Co. Zepbound injection pen, March 28, 2024.
Bloomberg | Bloomberg | Getty Images

Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed.

Products You May Like

Articles You May Like

Shortage of Novo Nordisk’s Wegovy and Ozempic drugs is resolved, FDA says
Celebrities Love the “80/20 Rule Diet” — Do Dietitians?
Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
Hims & Hers shares plunge 28% on concerns over weight loss business, margins
Beef Barley Soup

Leave a Reply

Your email address will not be published. Required fields are marked *